Advances in Molecular Diagnosis of Neurofibromatosis Type 1

被引:26
|
作者
Shofty, Ben [1 ,3 ]
Constantini, Shlomi [1 ,2 ,3 ]
Ben-Shachar, Shay [3 ,4 ]
机构
[1] Tel Aviv Univ, Tel Aviv Med Ctr, Sackler Fac Med, Div Neurosurg, IL-69978 Tel Aviv, Israel
[2] Tel Aviv Univ, Tel Aviv Med Ctr, Sackler Fac Med, Dept Pediat Neurosurg, IL-69978 Tel Aviv, Israel
[3] Tel Aviv Univ, Tel Aviv Med Ctr, Sackler Fac Med, Gilbert Israeli Neurofibromatosis Ctr, IL-69978 Tel Aviv, Israel
[4] Tel Aviv Univ, Tel Aviv Med Ctr, Sackler Fac Med, Genet Inst, IL-69978 Tel Aviv, Israel
关键词
PREIMPLANTATION GENETIC DIAGNOSIS; NF1; GENE; MUTATIONS; PHENOTYPE; GENOTYPE; SPECTRUM; INACTIVATION; EXPRESSION; MOSAICISM; STENOSIS;
D O I
10.1016/j.spen.2015.10.007
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Neurofibromatosis 1 (NF1) is a common neurocutaneous and tumor predisposing genetic disorder with an autosomal dominant mode of inheritance. NF1 is solely caused by mutations in the NF1 gene, and disease-causing mutations can be found in more than 95% of individuals with a clinical diagnosis. Although NF1 has a distinctive clinical phenotype, it has a highly variable expression, even among individuals from the same family. Identifying the specific mutation does not usually assist in determining disease course and severity, and relatively few genotype-phenotype correlations have thus far been found. This review discusses the basic clinical aspects of NF1 and the current explanations for the high phenotypic variability, and provides the recently detected genotype-phenotype correlations. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:234 / 239
页数:6
相关论文
共 50 条
  • [1] Molecular diagnosis strategies in neurofibromatosis type 1
    Bhouri, R.
    Hebrard, B.
    Wolkenstein, P.
    Funalot, B.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2020, 147 (03): : 247 - 251
  • [2] Neurofibromatosis Type 1 Molecular Diagnosis in Turkish Patients
    Bahsi, Taha
    Saat, Hanife
    GAZI MEDICAL JOURNAL, 2020, 31 (03): : 406 - 409
  • [3] Molecular diagnosis of neurofibromatosis type 1: 2 years experience
    Griffiths, Sian
    Thompson, Peter
    Frayling, Ian
    Upadhyaya, Meena
    FAMILIAL CANCER, 2007, 6 (01) : 21 - 34
  • [4] Molecular diagnosis of neurofibromatosis type 1: 2 years experience
    Siân Griffiths
    Peter Thompson
    Ian Frayling
    Meena Upadhyaya
    Familial Cancer, 2007, 6 : 21 - 34
  • [5] Neurofibromatosis Type 1 Molecular Diagnosis: The RNA Point of View
    Pasmant, Eric
    Vidaud, Dominique
    EBIOMEDICINE, 2016, 7 : 21 - 22
  • [6] Recent advances in neurofibromatosis type 1
    Arun, D
    Gutmann, DH
    CURRENT OPINION IN NEUROLOGY, 2004, 17 (02) : 101 - 105
  • [7] The Diagnosis and Management of Neurofibromatosis Type 1
    Ly, K. Ina
    Blakeley, Jaishri O.
    MEDICAL CLINICS OF NORTH AMERICA, 2019, 103 (06) : 1035 - +
  • [8] Diagnosis and management of neurofibromatosis type 1
    Korf B.R.
    Current Neurology and Neuroscience Reports, 2001, 1 (2) : 162 - 167
  • [9] Molecular diagnosis as a strategy for differential diagnosis and at early ages of neurofibromatosis type 1 (NF1)
    Gomez, Martha
    Batista, Oriana
    REVISTA MEDICA DE CHILE, 2015, 143 (10) : 1320 - 1330
  • [10] Molecular diagnosis of Neurofibromatosis Type 1 (NF1): An 18 months experience
    Griffiths, S
    Frayling, I
    Upadhyaya, M
    JOURNAL OF MEDICAL GENETICS, 2005, 42 : S97 - S97